comparemela.com

Latest Breaking News On - European regulatory - Page 1 : comparemela.com

Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript

Novo Nordisk A/S misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.77.

United statesDoug langaMichael nedelcovychMartin holst langeRichard vosserDaniel muusmann bohsenCamilla sylvestDaniel bohsenLars fruergaardNovo nordiskKarsten munk knudsenLouise chenEuropean renal association congressCatalenta global contract developmentCardior pharmaceuticalsNovo holdings

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic .

United statesRandy milbyTharimmune incNational institute of diabetesNational institutes of healthNews networkEuropean regulatoryWorst itch numerical rating scaleNational instituteKidney diseasesNational institutes

Tharimmune (THAR) Reports Positive Phase 1 Data on TH104

Tharimmune (THAR) Reports Positive Phase 1 Data on TH104
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRandy milbyNational institute of diabetesNational institutes of healthTharimmune incEuropean regulatoryWorst itch numerical rating scaleNational instituteKidney diseasesNational institutes

Tharimmune Shares Rise On Positive Phase 1 Data On TH104

Shares of Tharimmune, Inc. (THAR) are up 33% on Monday after the company announced positive phase 1 data for its proprietary transmucosal buccal film product, TH104, that adheres easily to the inside of the mouth, making it a convenient solution for patients.

United statesTharimmune incEuropean regulatory

EMA grants PRIME designation to Rocket s AAV-based gene therapy

The EMA has granted PRIME designation to Rocket’ adeno-associated virus (AAV)-based gene therapy, RP-A501, for the treatment of Danon Disease.

Kinnari patelYork heart associationNew york heart associationKansas city cardiomyopathy questionnaireEuropean regulatory

vimarsana © 2020. All Rights Reserved.